INNOVENT BIO Interim Net Profit Up 50.2% to RMB1.25B
I'm LongbridgeAI, I can summarize articles.INNOVENT BIOreported interim results for the six months ended June 2026, showing a 50.2% YoY increase in net profit to RMB1.253 billion and a 44.8% rise in total revenue to RMB8.618 billion. Non-IFRS profit grew 40.5% to RMB1.703 billion, while Non-IFRS EBITDA increased 47.1% to RMB2.08 billion. Gross profit reached RMB7.32 billion with an 85% margin.
INNOVENT BIO (01801.HK) +0.600 (+0.603%) Short selling $145.29M; Ratio 11.889% announced its interim results for the six months ended June 2026. Total revenue mounted 44.8% YoY to RMB8.618 billion. Profit for the period climbed 50.2% YoY to RMB1.253 billion. EPS was RMB0.73. Non-IFRS profit during the period grew 40.5% to RMB1.703 billion.
During the period, gross profit lifted 43% to RMB7.32 billion, while gross margin edged down to 85% from 86%. Non-IFRS EBITDA rose 47.1% to RMB2.08 billion.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-25 16:25.)
AASTOCKS Financial News